The Architects.
AI expertise meets medical device excellence. A rare combination for a unique challenge.
The device presented is under preclinical/clinical investigation. It is not FDA approved nor CE labelled.
Board of Directors
Strategic oversight and capital allocation.
Sam Errama
Platform architecture and AI strategy. Drives board-level decisions on technology roadmap, regulatory posture, and capital deployment.
Taha Errama
Governance and technology oversight across the hardware, optical, and AI stack.
Executive Team
The team that built the system is the team commercializing it.
Christophe Bailleul
25+ years in atrial fibrillation, with deep expertise in clinical trial design, market access and reimbursement strategy. Led biventricular pacemaker clinical development through CE/PMA and integration into medical guidelines. Previously VP and Director at ELA/Sorin, St. Jude Medical and Mauna Kea Technologies. Co-founder of Co-Decision Technology S.A.S.
- Clinical trial design and execution
- FDA and EU MDR regulatory pathways
- Medical device quality management system
Lucía Colmenero
15+ years in banking, international controllership and financial management of high-growth technology start-ups. Previously Financial Manager for SMEs at “la Caixa” and financial lead at Integromics (acquired by PerkinElmer in 2014). Significant experience with public funding and national and European programmes.
- Corporate finance and planning
- Capital deployment against the Series A plan
- Operations and people
David Herranz
18+ years in research and medical device development, with 12 years leading preclinical programmes, regulatory documentation and multidisciplinary technical teams, including the execution of several clinical trials. Project leader on three programmes funded by the Spanish Ministry of Science and Innovation through public-private collaborations. Specialist in ablation systems for atrial fibrillation, with end-to-end project execution expertise. Twenty-plus peer-reviewed publications.
- Preclinical model design and execution
- Clinical study operations and site coordination
- Translational evidence for the AI Engine
Abel Roige
Bachelor’s in Materials Engineering and PhD in Materials Science and Optical Characterisation. 10+ years leading R&D projects across multidisciplinary teams, cutting-edge technologies and start-up environments, including six years focused on the medical device industry. Extensive experience in product development and V&V activities for medical products, with contributions to multiple preclinical and clinical trials.
- Optical engineering and PS-OCR signal chain
- Console and catheter systems integration
- Technical roadmap toward regulatory submission
Co-authors and investigators
All have been co-authors on either the pre-clinical or first-in-human publications. Listed alphabetically by surname.
Prof. Raphaël Martins, MD, PhD
Co-author on the AblaView® first-in-human publication (Europace, February 2025). Proctor during the first-in-human cases.
Dr. Maria Terricabras, MD
Lead author of the AblaView® PS-OCR pre-clinical study (Circulation, 2024). Specialist in preclinical evaluation of novel ablation devices.
Prof. Atul Verma, MD
Co-author on the AblaView® first-in-human publication (Europace, February 2025). Proctor during the first-in-human cases.
Additional co-authors
Including Prof. Giorgi Papiashvili and the full author lists recorded in the Europace (2025) and Circulation (2024) publications.
Why This Team Wins
Most medical device companies lack AI expertise. Most AI companies lack medical device experience. AblaView® has both.
We bridge the gap between cutting-edge machine learning and the rigorous safety requirements of the cardiac cath lab.